Dowpharma Completes Technology Transfer to Cambrex
EAST RUTHERFORD, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Cambrex Bio
Science Baltimore, Inc., a subsidiary of Cambrex Corporation (NYSE: CBM), and
Dowpharma(SM) contract manufacturing services, a business unit of The Dow
Chemical Company (NYSE: DOW), are pleased to announce they have entered into
an agreement to utilize the Pfenex Expression Technology(TM), a Pseudomonas-
based technology, from Dowpharma. The relationship includes an initial
technology transfer production run, the establishment of a standardized
technology transfer package for customer projects, and the collaborative
interactions between Cambrex, Dowpharma and third-party product companies to
allow for Cambrex to successfully manufacture biologic drug substances using
the Pfenex Expression Technology.
"We expect Dowpharma's Pfenex Expression Technology to greatly increase
protein expression levels in our customers' processes," said Frank Marchesani,
Director of Sales and Business Development, Cambrex Biopharma business. "The
performance of the Pfenex Expression Technology in our initial production run
confirmed the power of this exciting expression technology."
"Cambrex is impressed by the superior growth performance and expression
characteristics of the Pfenex technology compared to conventional Escherichia
coli based systems," added Christopher Dale, Ph.D., Vice President Technology,
Cambrex Biopharma business. "The complementary services offered by Dowpharma
and Cambrex scientists, combined with standardized technology transfer
protocols, will streamline the transition of customer projects from Dowpharma
to Cambrex."
"We are pleased to work with Cambrex to help them leverage Pfenex
Expression Technology to cost effectively deliver higher yields of their
customers' therapeutic proteins," said Patrick Lucy, Business Leader,
Microbial Biopharmaceuticals, Dowpharma. "As a leading cGMP service provider,
Cambrex will be an important part of the manufacturing network supporting the
Pfenex Expression Technology."
Dowpharma has an unmatched record in developing high-productivity strains
for the manufacture of numerous protein products, for both clinical and
industrial applications. The Pfenex Expression Technology accelerates speed
to market for vaccines and biotherapeutics by improving quality, boosting
yields and reducing the cost of existing microbial systems. Pfenex Expression
Technology(TM) is built around specially modified strains of Pseudomonas
fluorescens bacteria that increase cellular expression of recombinant proteins
and peptides while maintaining critical solubility and activity
characteristics. Pfenex Expression Technology consistently outperforms other
microbial systems, often with yields of five to ten times the next best
expression alternative.
About Cambrex
Cambrex is a global, diversified life sciences company dedicated to
providing products and services to accelerate and improve the discovery and
commercialization of human therapeutics. The Company employs approximately
1900 worldwide. For more information, please visit http://www.cambrex.com.
Since the mid-1990s, Cambrex has helped customers develop their active
pharmaceutical ingredients (APIs) and drug substances more efficiently and
cost-effectively. The Company has diagnosed and overcome problems that
clients had in their manufacturing processes, provided clinical or commercial
quantities of hundreds of pharmaceutical products and provided the analytical,
regulatory and other support services that clients need to shorten the time to
market. More recently, the Company expanded into the product
commercialization arena with sales and marketing services. The combined
strength of experience, breadth of products and services and success
integrating over twenty acquisitions supports the Company's strategy to move
into the specialty therapeutics market.
About Dowpharma
Dowpharma(SM) serves the pharmaceutical and biopharmaceutical industries
with innovative technologies, products, and services in drug discovery,
development, delivery and manufacturing. Dowpharma has one of the broadest
and deepest capabilities in the global outsourcing industry with services that
include process development, route selection, methods development, custom
solubilization, chiral capabilities, and associated analytical services, as
well as manufacturing and scale-up from feasibility, through clinical trials,
to commercial manufacturing.
Dowpharma manufactures small molecule Active Pharmaceutical Ingredients
(APIs) and intermediates, nucleic acid medicines, cGMP polymers, peptides and
therapeutic proteins from microbial fermentation and plant-based systems.
Dowpharma draws upon over 30 years of excellent cGMP regulatory compliance in
the organic synthesis of APIs and pharmaceutical intermediates with the
ability to provide client support in filing and validation strategies.
Dowpharma operates research, process development, and manufacturing facilities
in North America and Europe. More information is available at
http://www.dowpharma.com.
About Dow
Dow is a leader in science and technology, providing innovative chemical,
plastic and agricultural products and services to many essential consumer
markets. With annual sales of $40 billion, Dow serves customers in 175
countries and a wide range of markets that are vital to human progress: food,
transportation, health and medicine, personal and home care, and building and
construction, among others. Committed to the principles of sustainable
development, Dow and its 43,000 employees seek to balance economic,
environmental and social responsibilities. References to "Dow" or the
"Company" mean The Dow Chemical Company and its consolidated subsidiaries
unless otherwise expressly noted.
(SM) Service Mark of The Dow Chemical Company
(R)(TM)* Trademark of The Dow Chemical Company ("Dow") or an affiliated
company of Dow
Forward Looking Statements
This news release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under
The Securities Exchange Act of 1934, including, without limitation, statements
regarding expected performance, especially expectations with respect to sales,
research and development expenditures, earnings per share, capital
expenditures, acquisitions, divestitures, collaborations, or other expansion
opportunities. These statements may be identified by the fact that words such
as "expects," "anticipates," "intends," "estimates," "believes" or similar
expressions are used in connection with any discussion of future financial and
operating performance. The forward-looking statements contained herein are
based on current plans and expectations and involve risks and uncertainties
that could cause actual outcomes and results to differ materially from current
expectations including but not limited to, global economic trends,
pharmaceutical outsourcing trends, competitive pricing or product
developments, government legislation and/or regulations (particularly
environmental issues), tax rate, interest rate, technology, manufacturing and
legal issues, changes in foreign exchange rates, performance of minority
investments, un-collectable receivables, loss on disposition of assets,
cancellation or delays in renewal of contracts, and lack of suitable raw
materials or packaging materials. For further details and a discussion of
these and other risks and uncertainties, investors are cautioned to review the
Cambrex Annual Report on Form 10-K, including the Forward-Looking Statement
section therein, and other filings with the Securities and Exchange
Commission. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.
SOURCE Cambrex Corporation; Dowpharma
 back to top
Related links:
http://www.cambrex.com
http://www.dowpharma.com
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
CONTACT:
Anne-Marie Hess, Sr. Director, Investor
Relations & Corporate Communications of Cambrex, +1-201-804-3062,
annemarie.hess@cambrex.com; or Kathy W. Sweeney of Mentus for
Dowpharma, +1-858-455-5500, x230, kwitz@mentus.com
|
